Global Age-related Macular Degeneration Drugs Market Size Study, by Product, by Molecule, by Approval Type, by Type of AMD, and Regional Forecasts 2022-2032

Description

The Global Age-related Macular Degeneration (AMD) Drugs Market is currently valued at approximately USD 9.45 billion in 2023 and is forecasted to grow at an impressive CAGR of 10.70% over the forecast period from 2024 to 2032. Age-related macular degeneration, a leading cause of vision impairment in aging populations worldwide, has propelled significant innovations in pharmacological interventions. Advanced treatments, such as biologics and biosimilars, are shaping a new era of therapeutic efficacy, focusing on slowing disease progression and improving patients' quality of life.

Pharmaceutical advancements like Lucentis, Eylea HD, and the novel Syfovre, alongside emerging biosimilars, are fueling the market's growth trajectory. The rise in patient awareness about early intervention and increasing healthcare expenditure in ophthalmology further amplify the demand for AMD therapies. Notably, the integration of personalized medicine into treatment protocols is a defining trend, offering tailored solutions that optimize therapeutic outcomes while minimizing adverse effects. Despite these advances, the high cost of biologic drugs and regulatory complexities surrounding biosimilar approvals may pose challenges to market participants during the forecast period.

Regionally, the AMD drugs market exhibits diverse growth dynamics. North America commands the largest market share, underpinned by robust healthcare infrastructure, high prevalence of AMD, and substantial investment in R&D initiatives. Europe follows closely, driven by strong government support and the adoption of advanced biologics. Meanwhile, the Asia-Pacific region is expected to record the fastest growth, attributed to increasing healthcare investments, rising geriatric populations, and enhanced access to ophthalmic care across emerging economies like China and India.

Major market players included in this report are:

1. Regeneron Pharmaceuticals, Inc.
2. Roche Holding AG
3. Novartis AG
4. Bayer AG
5. Biogen Inc.
6. Alimera Sciences
7. Adverum Biotechnologies, Inc.
8. Eyepoint Pharmaceuticals
9. Outlook Therapeutics, Inc.
10. Apellis Pharmaceuticals, Inc.
11. Amgen Inc.
12. Pfizer Inc.
13. Samsung Bioepis
14. Intas Pharmaceuticals
15. Santen Pharmaceutical Co., Ltd.

The detailed segments and sub-segments of the market are explained below:

By Product:

Lucentis
Eylea & Eylea HD
Vabysmo
Syfovre

By Molecule:

Ranibizumab
Aflibercept
Faricimab

By Approval Type:

Biologic
Biosimilar

By Type of AMD:

Wet AMD
Dry AMD

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Comprehensive revenue analysis and forecasts for a 10-year period (2022-2032).
Detailed segmentation and regional insights for North America, Europe, APAC, Latin America, and MEA.
Competitive landscape profiling major industry players with strategic recommendations for market expansion.
Examination of emerging trends like biosimilar approvals and personalized medicine applications.
Demand-side and supply-side assessments to identify growth opportunities and market challenges.

Chapter 1. Global Age-related Macular Degeneration (AMD) Drugs Market Executive Summary

1.1. Global AMD Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Molecule
- 1.3.3. By Approval Type
- 1.3.4. By Type of AMD
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global AMD Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global AMD Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Prevalence of AMD
- 3.1.2. Advancements in Biologic and Biosimilar Therapies
- 3.1.3. Rising Healthcare Expenditure in Ophthalmology
3.2. Market Challenges
- 3.2.1. High Cost of Biologic Drugs
- 3.2.2. Regulatory Complexities Surrounding Biosimilars
3.3. Market Opportunities
- 3.3.1. Growth in Personalized Medicine
- 3.3.2. Rising Patient Awareness and Early Intervention
- 3.3.3. Expansion in Emerging Markets

Chapter 4. Global AMD Drugs Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global AMD Drugs Market Size & Forecasts by Product 2022-2032

5.1. Segment Dashboard
5.2. Global AMD Drugs Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Lucentis
- 5.2.2. Eylea & Eylea HD
- 5.2.3. Vabysmo
- 5.2.4. Syfovre

Chapter 6. Global AMD Drugs Market Size & Forecasts by Molecule 2022-2032

6.1. Segment Dashboard
6.2. Global AMD Drugs Market: Molecule Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Ranibizumab
- 6.2.2. Aflibercept
- 6.2.3. Faricimab

Chapter 7. Global AMD Drugs Market Size & Forecasts by Approval Type 2022-2032

7.1. Segment Dashboard
7.2. Global AMD Drugs Market: Approval Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Biologic
- 7.2.2. Biosimilar

Chapter 8. Global AMD Drugs Market Size & Forecasts by Type of AMD 2022-2032

8.1. Segment Dashboard
8.2. Global AMD Drugs Market: Type of AMD Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.2.1. Wet AMD
- 8.2.2. Dry AMD

Chapter 9. Global AMD Drugs Market Size & Forecasts by Region 2022-2032

9.1. North America AMD Drugs Market
- 9.1.1. U.S. AMD Drugs Market
  - 9.1.1.1. Product Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.2. Molecule Breakdown Size & Forecasts, 2022-2032
- 9.1.2. Canada AMD Drugs Market
9.2. Europe AMD Drugs Market
- 9.2.1. UK AMD Drugs Market
- 9.2.2. Germany AMD Drugs Market
- 9.2.3. France AMD Drugs Market
- 9.2.4. Spain AMD Drugs Market
- 9.2.5. Italy AMD Drugs Market
- 9.2.6. Rest of Europe AMD Drugs Market
9.3. Asia-Pacific AMD Drugs Market
- 9.3.1. China AMD Drugs Market
- 9.3.2. India AMD Drugs Market
- 9.3.3. Japan AMD Drugs Market
- 9.3.4. Australia AMD Drugs Market
- 9.3.5. South Korea AMD Drugs Market
- 9.3.6. Rest of Asia Pacific AMD Drugs Market
9.4. Latin America AMD Drugs Market
- 9.4.1. Brazil AMD Drugs Market
- 9.4.2. Mexico AMD Drugs Market
- 9.4.3. Rest of Latin America AMD Drugs Market
9.5. Middle East & Africa AMD Drugs Market
- 9.5.1. Saudi Arabia AMD Drugs Market
- 9.5.2. South Africa AMD Drugs Market
- 9.5.3. Rest of Middle East & Africa AMD Drugs Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Regeneron Pharmaceuticals, Inc.
- 10.1.2. Roche Holding AG
- 10.1.3. Novartis AG
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Regeneron Pharmaceuticals, Inc.
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Bayer AG
- 10.3.3. Biogen Inc.
- 10.3.4. Alimera Sciences
- 10.3.5. Adverum Biotechnologies, Inc.
- 10.3.6. Eyepoint Pharmaceuticals
- 10.3.7. Outlook Therapeutics, Inc.
- 10.3.8. Apellis Pharmaceuticals, Inc.
- 10.3.9. Amgen Inc.
- 10.3.10. Pfizer Inc.
- 10.3.11. Samsung Bioepis
- 10.3.12. Intas Pharmaceuticals
- 10.3.13. Santen Pharmaceutical Co., Ltd.

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes